United Kingdom-based Immune Targeting Systems (ITS) showed data from a Phase IIa trial of its candidate, Flunisyn, at the World Vaccine Congress this week.
When scientists advising President Obama came to analyze the U.S. response to the outbreak of H1N1, they identified several major bottlenecks that needed clearing. Poor yields from seed viruses were near the top of the list, and the scientists set a two year target for improving.
The Swedish regulator has added to evidence linking GlaxoSmithKline's swine flu vaccine to narcolepsy in a registry study of 5.8 million people.
Flu has always presented a moving target for developers, with rapid evolution keeping viruses one step ahead of vaccines. In pandemic flu, mutations could turn a relatively benign virus into one that is more virulent, capable of spreading from human to human or resistant to drugs.
After winning FDA approval for its influenza vaccine in January, Protein Sciences was faced with a problem: how to wrest market share from competitors. The task is complicated by the fact that, as yet, there is little evidence to show it is more effective than rivals.
Cambridge, MA-based Vertex Pharmaceuticals says it nailed solid mid-stage data for VX-787, an experimental influenza drug in a new class of medications that promises to prevent the virus from replicating. And the biotech added that it will be in hot pursuit of a new collaboration on the drug.
It will be a different influenza vaccine market moving forward. After years of consideration, an FDA panel has given its approval to quadrivalent or four-strain vaccines. It should be a boost to consumers who suffered through a particularly bad flu season this year and to the two companies that already have quadrivalents approved, GlaxoSmithKline and AstraZeneca's MedImmune.
Low efficacy of this season's flu vaccine highlights the need for vaccinemakers to develop a better, longer-lasting shot. Only 56% of people who received the jab were protected from influenza, the U.S. Centers for Disease Control and Prevention reports, and the elderly were among the least shielded.
Though the United States has made significant progress in the realm of flu vaccines, the country will likely need to wait 5 to 10 years for a universal shot, top federal health officials said.
For years now, evidence has been mounting that a GlaxoSmithKline flu vaccine may have caused narcolepsy in nearly 800 Europeans who received the shot. Now the jab's adjuvant--designed to boost the potency of the vaccine--is under the microscope as the potential cause of the spike in cases of the sleeping disorder.